Clinical trial

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

NCT05602792

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention T3011 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-04-21

PhasePHASE1 / PHASE2

Conditions

Advanced Solid Tumorunresolved

Sarcomaverified · MONDO: sarcoma

HNSCCverified · MONDO: head and neck squamous cell carcinoma

Breast Cancerverified · MONDO: breast cancer

Esophagus Cancerverified · MONDO: esophageal cancer

NSCLCverified · MONDO: non-small cell lung carcinoma

Non-melanoma Skin Cancerverified · MONDO: skin carcinoma

Interventions

T3011BIOLOGICAL

Sponsors & collaborators

ImmVira Pharma Co. Ltdlead sponsor

Mapped research locations

ShanghaiChina4 BeijingChina2 ZhengzhouHenan, China2 HefeiAnhui, China2 ChangshaHunan, China1 WuhanHubei, China1 ChengduSichuan, China1 ShenyangLiaoning, China1 NanchangJiangxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05602792 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.